This open-label study evaluated the efficacy and safety of a new leuprolide acetate 45 mg 6-month depot formulation in 151 men with prostate cancer who received 2 intramuscular injections administered ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results